Drug Trial Radar · NCT02435173
Study of Efficacy of CDZ173 in Patients With APDS/PASLI
Last checked: Nov 20, 2026Latest source record: Aug 10, 2022 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
37
Actual
Start
Aug 24, 2015
Primary completion
Aug 16, 2021
Study completion Aug 16, 2021
Sponsor
- Lead sponsor
- Novartis PharmaceuticalsNovartis (NVS)
- Sponsor type
- Industry
- First posted
- May 6, 2015
Design
- Study type
- Interventional
- Phase
- Phase 2 / Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, care provider, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 12 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study was designed to explore CDZ173, a selective PI3Kδ inhibitor, in patients with genetically activated PI3Kδ, i.e., patients with Activated phosphoinositide 3-kinase delta syndrome/ p110δ-activating mutation causing senescent T cells, lymphadenopathy and immunodeficiency (APDS/PASLI). The study consisted of two parts: Part I was the open label part designed to establish the safety and pharmacokinetics of CDZ173 in the target population, as well as to select the optimal dose to be tested in Part II. Part II was designed to assess efficacy and safety of CDZ173 in the target population.
Conditions
- Common Variable Immunodeficiency (CVID), APDS / PASLI
Interventions
CDZ173Drug
CDZ173 10 and 70 mg capsules for oral administration.
PlaceboOther
Placebo capsules for oral administration
Primary outcomes
What the sponsor says the trial is designed to measure.
- Part I: Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)Time frame: From the start of treatment to 30 days after end of treatment, assessed up to maximum duration of 114 days
- Part I: CDZ173 Dose ConcentrationTime frame: Days 1, 29 and 57 (0.25 and 3 h post morning dose) and Day 84
- Part I: Percentage of Inhibition of Unstimulated and Stimulated pAkt Levels in B CellsTime frame: Baseline, days 29 and 57 (3 and 12 h post-dose) and day 84
- Part II: Change From Baseline in the log10 Transformed Sum of Product of Diameters (SPD) in the Index LesionsTime frame: Baseline and Day 85
- Part II: Change From Baseline in Percentage of naïve B Cells Out of Total B CellsTime frame: Baseline and Day 85
Locations
10 sites in 9 countries. Site status is shown where the registry gives one.
National Institute of Health NIH
Bethesda, Maryland
Novartis Investigative Site
Minsk, Belarus
Novartis Investigative Site
Prague, Czechia
Novartis Investigative Site
Dresden, Germany
Novartis Investigative Site
Dublin, Ireland
Novartis Investigative Site
Brescia, Italy
Novartis Investigative Site
Palermo, PA, Italy
Novartis Investigative Site
Rotterdam, Netherlands
Novartis Investigative Site
Moscow, Russia
Novartis Investigative Site
Belfast, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.